A detailed history of Belmont Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Belmont Capital, LLC holds 23,312 shares of GILD stock, worth $2.09 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
23,312
Previous 3,684 532.79%
Holding current value
$2.09 Million
Previous $269,000 494.42%
% of portfolio
0.3%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $1.24 Million - $1.43 Million
19,628 Added 532.79%
23,312 $1.6 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $248,586 - $271,212
3,362 Added 1044.1%
3,684 $276,000
Q2 2023

Aug 10, 2023

BUY
$76.01 - $86.7 $6,840 - $7,803
90 Added 38.79%
322 $24,000
Q1 2023

May 09, 2023

BUY
$77.31 - $88.08 $8,967 - $10,217
116 Added 100.0%
232 $19,000
Q3 2022

Oct 18, 2022

BUY
$59.54 - $68.01 $6,906 - $7,889
116 New
116 $7,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Belmont Capital, LLC Portfolio

Follow Belmont Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belmont Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belmont Capital, LLC with notifications on news.